In 2017, De Bono et al. [70] conducted the first-in-human dose escalation trial of talazoparib in patients with advanced solid tumors harboring germline BRCA1/2 mutation or tumours potentially sensitive to PARP inhibitors. Here, BRCA1 is linked to neoplasm.